Pembrolizumab with carboplatin and paclitaxel for untreated advanced or recurrent endometrial cancer [ID6381] Draft guidance Technology appraisal guidance 14 April 2025 Natalizumab (originator and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback